Back to results
US 2026/0232694 A1Published application
Inhalable hormone receptor agonist formulations
AssigneePinata Holdings Inc.
InventorsMichael OGBURN, Christopher PRICE
Life of this patent
Estimating the term…
Abstract
Provided herein are pharmaceutical compositions, kits comprising pharmaceutical compositions, methods of treating disease, and methods of making compositions and kits described herein. The pharmaceutical compositions described herein are powdery pharmaceutical compositions. The powdery pharmaceutical compositions may be administered by an inhaler device described herein. The powdery pharmaceutical compositions may be administered by gummies described herein.
Claims65
A powdery pharmaceutical composition, comprising:
- a) particles of a pharmaceutically acceptable excipient;
- and
- b) a plurality of spray dried particles, wherein each particle of the plurality of spray dried particles is substantially encapsulated in a coating material and wherein the plurality of spray dried particles substantially encapsulated in the coating material comprise:
- an agonist selected from the group consisting of:
- a steroid or a pharmaceutically acceptable salt thereof, a human growth hormone receptor agonist or a pharmaceutical acceptable salt thereof, and a glucagon-like peptide 1 receptor agonist or a pharmaceutical acceptable salt thereof;
- and
- wherein within the plurality of spray dried particles substantially encapsulated in the coating material at least a portion of the spray dried particles substantially encapsulated in the coating material individually have a particle diameter ranging from about 1 micrometer to about 10 micrometers, as measured by a particle analyzer using laser diffraction;
- and
- wherein the coating material comprises a trehalose, a hydroxypropyl methylcellulose (HPMC), a fumaryl diketopiperazine (FDKP), a 1,2-distearoyl-sn-glycero-3-phosphocholine, a hydroxypropyl methylcellulose acetate succinate (HPMCAS), a povidone, a copovidone, a lactose, a phospholipid or any combination thereof.
6 more elements
A powdery pharmaceutical composition, comprising:
- particles of a pharmaceutically acceptable carrier;
- and
- a plurality of spray dried particles, wherein each particle of the plurality of spray dried particles is substantially unencapsulated and wherein the plurality of spray dried particles substantially unencapsulated comprise:
- an agonist selected from the group consisting of:
- a steroid or a pharmaceutically acceptable salt thereof, a human growth hormone receptor agonist or a pharmaceutical acceptable salt thereof, and a glucagon-like peptide 1 receptor agonist or a pharmaceutical acceptable salt thereof;
- and
- wherein within the plurality of spray dried particles, the spray dried particles comprise a mass median aerodynamic diameter of less than 5 μm and a fine particle fraction of at least about 40% upon aerosolization;
- and
- wherein pharmaceutically acceptable carrier comprises trehalose, a hydroxypropyl methylcellulose (HPMC), a fumaryl diketopiperazine (FDKP), 1,2-distearoyl-sn-glycero-3-phosphocholine, a hydroxypropyl methylcellulose acetate succinate (HPMCAS), a povidone, a copovidone, a lactose, a phospholipid, or any combination thereof.
6 more elements
Dependencies are inferred from the claim text.